Clinical Trials · uk
Long-used liver drug UDCA joins phase 3 Parkinson’s trial to test whether it can slow disease progression
From drug screening in patient-derived cells to a large clinical trial, UDCA has become the third drug tested in EJS ACT-PD. Early signals in brain energy metabolism provide a rationale for the research; whether they translate into slower disease progression will undergo more rigorous testing.
One challenge in treating Parkinson’s disease is finding ways to slow its progression. Now, a drug long used for liver disease will be put to that test: on November 4, the UK EJS ACT-PD trial team announced that the ursodeoxycholic acid (UDCA) treatment arm had opened, making it the third drug tested in this phase 3 platform trial, alongside telmisartan and terazosin, to assess its potential to slow disease progression.
The trial is jointly led by researchers at University College London (UCL) and Newcastle University and coordinated by the UCL Comprehensive Clinical Trials Unit. According to the University of Sheffield, the overall programme plans to recruit 2,000 people across 40 NHS hospital sites in the UK. UCL’s November 4 update reported that 26 sites had opened and more than 189 participants had been randomised. These recruitment figures cover the entire platform, rather than the UDCA treatment arm alone.
Research into UDCA began with drug screening by the Sheffield team using tissue derived from people with Parkinson’s disease. Researchers were interested in its potential to improve mitochondrial function: mitochondria supply energy to cells, and impaired energy supply in the brain’s dopamine-producing nerve cells is thought to be associated with disease progression. This line of research aims to reduce ongoing damage to nerve cells by maintaining cellular function.
Evidence supporting UDCA’s move into a large trial includes observations of safety, tolerability and preliminary signals in brain energy metabolism from the earlier phase 2 UP study. However, changes in metabolic measures do not establish that disease progression has slowed in patients, and safety findings from an early trial cannot replace follow-up on a larger scale. This announcement offers an opportunity for further testing; phase 3 efficacy results have not yet been announced.
EJS ACT-PD uses a “multi-arm, multi-stage” design, allowing several candidate therapies to be evaluated within the same trial framework and new drugs to be added as evidence accumulates. The opening of the UDCA treatment arm is a concrete application of this flexibility. Compared with setting up a separate trial for each drug, this approach could improve research efficiency. Whether a drug can slow disease progression must still be determined through comparison with placebo.
With the addition of UDCA, eligible new participants will be randomly assigned to one of three drug arms or two placebo arms. Neither participants nor the research team will know the assignments during the trial. The use of two placebo arms relates to differences between how UDCA and the other two drugs are taken. According to Parkinson’s UK, the number of tablets taken daily in the UDCA arm will be adjusted by body weight to three, four or five to match the trial dose.
Background
Drug development for Parkinson’s disease continues to explore disease-modifying therapies—treatments that aim to alter disease progression. All three drugs currently included in EJS ACT-PD were originally used for other diseases; telmisartan and terazosin have been used to treat high blood pressure. Existing experience with these drugs can provide a starting point for research, but their use in Parkinson’s disease still requires the central question to be answered: can effects on cellular mechanisms deliver sustained benefits that patients can perceive in their daily lives?